CCMB, a part of the Council of Scientific and Industrial Research (CSIR), has signed a comprehensive MoU (Agnitha's Generative AI MoU) to implement small molecule and Solutions for antibody design.
Initial areas of collaboration include target analysis, small molecule design and antibody and nanobody engineering to address malaria, tuberculosis (TB) and neurological disorders.
This strategic collaboration is designed to translate discoveries from CCMB's globally acclaimed research laboratories into therapeutic candidates through the application of Agnitha's generative AI solutions to biopharma R&D, the joint statement on Wednesday said.
“We continue to struggle to control malaria due to drug resistance of the pathogen, lack of widely available vaccines, and insecticide resistance of mosquitoes.Collaborative efforts of interdisciplinary experts are essential to develop new drugs and vaccines for malaria. Towards this goal, we are using Agnetha's generative approach in the small molecules space to validate parasite drug targets to predict, test and optimize potential anti-malarial compounds,” said Senior Principal Scientist of CCMB “Take advantage of AI capabilities,” said Dr. Puran Singh Sijwali.
Dr. Raghunanda Tirumalai, Senior Principal Scientist, CCMB, said they will work towards structure-based discovery of small molecule inhibitors targeting essential proteins of Mycobacterium tuberculosis, with the hope that this will lead to the identification of several novel antagonists. t Clinical leadership.
“The collaboration between CSIR-CCMB and Agnitha to develop nanobody binders targeting a class of neurotransmitter receptors called GluD1 receptors marks a significant advancement in neuroscience and pharmacology.These nanobodies modify GluD1 receptor activity. It could serve as a precise molecular tool for detecting neurological disorders such as Alzheimer's and epilepsy, potentially unlocking new treatments. With their small size and high specificity, the nanobody holds promise for targeted drug delivery and imaging applications, paving the way for tailored therapies with fewer side effects,” said Dr. Janesh Kumar, Senio Principal Scientist, CCMB.
“The collaboration with Agnitha is visionary, harnessing CCMB’s strengths in fundamental research on disease biology and Agnitha’s expertise in AI-driven solutions. It's great for us to see this kind of collaboration moving towards real-life solutions.“It is timely,” said Dr. Vinay Nandikoori, Director, CCMB.
Prasad Chodavarapu, Co-Founder and MD of Agnitha, sees the relationship between CCMB and Agnitha as a great example of the academic-industry collaboration needed to make a significant impact toward solving human diseases and suffering.
“We are a multidisciplinary team of researchers with expertise in multi-scale systems biology, quantum chemistry, and generative AI who are taking the opportunity to leverage the virtual loop of innovation happening between D science and deep tech to transform . Global life sciences research and development,” he said.
Initial areas of collaboration include target analysis, small molecule design and antibody and nanobody engineering to address malaria, tuberculosis (TB) and neurological disorders.
This strategic collaboration is designed to translate discoveries from CCMB's globally acclaimed research laboratories into therapeutic candidates through the application of Agnitha's generative AI solutions to biopharma R&D, the joint statement on Wednesday said.
“We continue to struggle to control malaria due to drug resistance of the pathogen, lack of widely available vaccines, and insecticide resistance of mosquitoes.Collaborative efforts of interdisciplinary experts are essential to develop new drugs and vaccines for malaria. Towards this goal, we are using Agnetha's generative approach in the small molecules space to validate parasite drug targets to predict, test and optimize potential anti-malarial compounds,” said Senior Principal Scientist of CCMB “Take advantage of AI capabilities,” said Dr. Puran Singh Sijwali.
Dr. Raghunanda Tirumalai, Senior Principal Scientist, CCMB, said they will work towards structure-based discovery of small molecule inhibitors targeting essential proteins of Mycobacterium tuberculosis, with the hope that this will lead to the identification of several novel antagonists. t Clinical leadership.
“The collaboration between CSIR-CCMB and Agnitha to develop nanobody binders targeting a class of neurotransmitter receptors called GluD1 receptors marks a significant advancement in neuroscience and pharmacology.These nanobodies modify GluD1 receptor activity. It could serve as a precise molecular tool for detecting neurological disorders such as Alzheimer's and epilepsy, potentially unlocking new treatments. With their small size and high specificity, the nanobody holds promise for targeted drug delivery and imaging applications, paving the way for tailored therapies with fewer side effects,” said Dr. Janesh Kumar, Senio Principal Scientist, CCMB.
“The collaboration with Agnitha is visionary, harnessing CCMB’s strengths in fundamental research on disease biology and Agnitha’s expertise in AI-driven solutions. It's great for us to see this kind of collaboration moving towards real-life solutions.“It is timely,” said Dr. Vinay Nandikoori, Director, CCMB.
Prasad Chodavarapu, Co-Founder and MD of Agnitha, sees the relationship between CCMB and Agnitha as a great example of the academic-industry collaboration needed to make a significant impact toward solving human diseases and suffering.
“We are a multidisciplinary team of researchers with expertise in multi-scale systems biology, quantum chemistry, and generative AI who are taking the opportunity to leverage the virtual loop of innovation happening between D science and deep tech to transform . Global life sciences research and development,” he said.
